Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oncodesign and the LNGT Enter into a Research Collaboration

Published: Wednesday, December 19, 2012
Last Updated: Wednesday, December 19, 2012
Bookmark and Share
Collaboration to advance Oncodesign's Parkinson’s disease program towards clinical development.

Oncodesign and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the department of neurosciences at the KU Leuven, an expert academic group exploring the roles of LRRK2 and a-synuclein in Parkinson’s disease headed by Professor Veerle Baekelandt, have announced that they have entered into a research collaboration to evaluate, with Ipsen, Oncodesign’s compounds in multiple pharmacology models for Parkinson's disease.

The collaboration builds on Oncodesign's LRRK2 program with advanced Nanocyclix® lead molecules that was partnered with Ipsen in January 2012.

“Our partnership with Ipsen on the discovery of novel therapeutic agents in Parkinson’s disease has advanced to a stage where we can use further in-depth expertise and advanced pharmacology models to position our leads. We are very excited to collaborate with KU Leuven to advance our understanding of both our inhibitors and the LRRK2 target,” said Jan Hoflack, Ph.D., chief scientific officer and head of Oncodesign's discovery activities.

“This collaboration with Oncodesign is a perfect example of translational research in action,” said Veerle Baekelandt, Ph.D., principle investigator of LNGT.

“Parkinson’s disease has been the focus of our research for more than ten years now. We are very pleased that Oncodesign has selected our lab as a partner for advancing their kinase program,” she added.

“We are thrilled that the expertise that our lab has built up from fundamental research on LRRK2 can be put to good use in evaluating and developing the biology aspects of compounds with therapeutic potential,” said Jean-Marc Taymans, Ph.D., group leader of LNGT.

“Ipsen and Oncodesign entered into a research collaboration last January for the development of new therapeutic agents against LRKK2 involved in Parkinson's disease, in line with our focus in neurology and movement disorders. We are delighted that our partnership with Oncodesign is moving forward as planned with the objective of developing therapeutics for Parkinson’s disease patients. The Oncodesign collaboration with LNGT will greatly accelerate the progress of this research program” stated Dr. Claude Bertrand, executive vice president, R&D, chief scientific officer at Ipsen.

Under the terms of the agreement, Oncodesign and LNGT will closely collaborate to advance Oncodesign's Parkinson’s disease program towards clinical development.

LNGT will receive full financial support from Oncodesign for these activities.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncodesign Enters into a Services Agreement with Eisai
The program aims to identify useful patient stratification biomarkers for Eisai’s Halaven® eribulin using patient-derived xenograft models.
Friday, December 26, 2014
Oncodesign and UCB Enter into a Research Collaboration
The partnership is based on Oncodesign's Nanocyclix® technology platform for next generation kinase inhibitors and UCB’s expertise in neurology.
Thursday, November 14, 2013
Oncodesign and Banook Central Imaging Sign a Collaboration Agreement
The global reaching partnership aims to provide clinical researchers with new biomarkers and validated image analysis protocols, ensuring a continuum from preclinical to clinical phase in the development of anticancer therapies.
Tuesday, September 10, 2013
Oncodesign Signs a Partnership Agreement with Sanofi
Oncodesign will apply its Nanocyclix® technology to one of Sanofi's kinase targets.
Tuesday, April 09, 2013
Oncodesign Signs Partnership Agreement with Sanofi
Oncodesign will apply its Nanocyclix(R) technology to one of Sanofi's kinase targets.
Thursday, March 28, 2013
Oncodesign and OSEO Announce Funding of EUR 13.4 Million
This private-public partnership project, which aims to put in place the first national subsidiary dedicated to personalized medicine in oncology, has a EUR 41 million overall investment budget.
Tuesday, March 12, 2013
Oncodesign Enters into a Research Collaboration and License Agreement with Sanofi
Collaboration for the application of Oncodesign’s Nanocyclix® technology to Sanofi’s kinase targets.
Saturday, September 15, 2012
Oncodesign and Ipsen Enter into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix(R) Technology for next generation kinase inhibitors and Ipsen’s expertise in Movement Disorders.
Thursday, January 05, 2012
Oncodesign and Ipsen Enter Into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix® technology for next generation kinase inhibitors and Ipsen’s expertise in movement disorders.
Thursday, January 05, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
NIH Launches Early-Stage Yellow Fever Vaccine Trial
Researchers at NIH have begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!